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Ghrelin is an endogenous peptide hormone mainly produced in the stomach. It has been
known to regulate energy homeostasis, stimulate secretion of growth hormone, and
mediate many other physiologic effects. Various effects attributed to ghrelin contribute
to many aspects of cancer development and progression. Accordingly, a large body of
evidence has emerged about the association of ghrelin with several types of cancer in
scales of cell-line, animal, and human studies. However, existing data are controversial.
This controversy occurs in two main domains: one is the controversial results in local
effects of ghrelin on different types of human cancer cell-lines; the second is the
apparent disagreement in the results of in-vitro and clinical studies that investigated
ghrelin association to one type of cancer. These inconsistencies have hampered the
indications to consider ghrelin as a potential tumor biomarker or therapeutic agent in
cancer patients. Previous studies have reviewed different parts of current literature about
the ghrelin-cancer relationship. Although they have highlighted these controversial results
in various ways, no specific recommendations have been given to address it. In this study,
we comprehensively reviewed in-vitro, in-vivo, and clinical studies and attempted to use
the following approaches to unravel the inconsistencies detected: (a) to distinguish local
and systemic effects of ghrelin in interpreting its summary clinical role in each cancer; (b)
scrutinizing factors that regulate local effects of ghrelin and could justify different effects of
ghrelin on different cancer cell-lines. These approaches could have notable implications
for future in-vitro and clinical studies.
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INTRODUCTION
Ghrelin is a peptide hormone that was discovered as an intrinsic ligand for growth hormone
secretagogue receptor (GHSR) (1). Ghrelin is mainly produced in des-acylated form by the gastric
oxyntic gland (Figure 1) (2–5). Other tissues including the lungs, kidneys, intestines, pancreas,
gonads, pituitary, and hypothalamus also produce lower levels of ghrelin (4–8). Ghrelin is encoded
by the GHRL gene, which is located in the short arm of chromosome 3 (3p25-26) (Figure 2)
(9). The initial GHRL gene product is a 117-amino acid pre-proprotein, called pre-proghrelin.
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FIGURE 1 | Overview of biological functions of ghrelin in body. Ghrelin is mainly produced in des-acylated form by gastric oxyntic gland and is acylated to active
ghrelin by GOAT enzyme. Ghrelin exerts its biological effects through binding to GHR-1, which is expressed predominantly on hypothalamus and less on other organs.
In contrast, des-acylated ghrelin functions as ghrelin antagonist and inhibits the function of ghrelin.
Pre-proghrelin contains a 23-amino acid N-terminal signal
peptide that is cleaved by signal peptidase in the endoplasmic
reticulum (5, 9). The remaining proghrelin peptide is then
split into 28-amino acid ghrelin and 66-amino acid C-ghrelin
peptides, by a prohormone convertase. Obestatin is another
regulatory hormone, which is generated by further processing of
C-ghrelin (5, 10).
Alternative splicing ofGHRL gene transcript leads to synthesis
of peptides other than native ghrelin, C-ghrelin, and Obestatin
(5, 11, 12). Exon 3-deleted pre-proghrelin and prepro-In1-
ghrelin are two products of alternative splicing that will be
discussed in more details later in this paper. Exon 3-deleted
preproghrelin apparently undergoes a processing similar to that
of preproghrelin, which gives rise to native ghrelin and a unique
carboxy-terminal peptide different from C-ghrelin (11). Prepro-
In1-ghrelin is the product of a messenger RNA, which retains the
intron1 transcript of the GHRL gene. After removal of the signal
peptide, the unique In1-ghrelin produced is larger than the native
ghrelin (12).
Total native ghrelin consists of acylated and des-acylated
ghrelins. Both forms are found in ghrelin-producing cells as well
as in the circulation (13). Acylation is a distinct post-translational
modification mediated by the enzyme Ghrelin-O-Acyltransferase
(GOAT) (5). During acylation, a fatty acid chain, mostly octanoyl
coenzyme A, is attached to the Serine 3 residue of proghrelin (5).
GOAT is present in ghrelin-producing cells and is predominantly
located in the endoplasmic reticulum membrane (14, 15).
Acylation seems to be a key regulatory mechanism of ghrelin
functions, since physiological concentrations of des-acylated
ghrelin cannot directly activate the main known ghrelin receptor,
GHS-R1a (16). Des-acylated from constitutes approximately
90% of total ghrelin in the circulation (17). Notably higher
concentrations of des-acylated ghrelin in the circulation may be
explained by: a larger proportion of ghrelin being secreted in
des-acylated form, conversion of acylated ghrelin to des-acylated
form in the circulation by serum esterase, and more stability
of des-acylated ghrelin in the circulation (5, 18). The half-life
of circulating des-acylated ghrelin is consistently reported to be
higher than the acylated form (19–21). In one study, elimination
half-lives of total and acylated ghrelin in human plasma were∼35
and 10min, respectively (19).
The current body of evidence supports notable complexity
in ghrelin axis, fed by both genetic and functional multiplicities
(22). Ghrelin exerts its paracrine and endocrine functions
through interactions with identified and unidentified receptors
on target cells (5). Ghrelin receptors characterized so far are two
splice variants of GHSR, type 1a (GHSR1a) and 1b (GHSR1b),
which are G protein-coupled and widely expressed. GHS-
R1a, which is considered the main functional receptor that
mediates most of the physiologic effects, is a transmembrane
G-protein coupled receptor (13). Acylated ghrelin is the only
form of ghrelin that can activate GHS-R1a (23, 24). The acyl
group is required for the conformational changes in ghrelin
peptide, which leads to activation of GHS-R1a (23). Upon
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FIGURE 2 | Gene transcription, alternative splicing, and post-translational modifications of ghrelin. Ghrelin is encoded by GHRL gene, which also can produce
peptides other than native ghrelin through alternative splicing. Exon 3-deleted peptide lacks the exon number 3 and In1-ghrelin is product of a messenger RNA, which
retains the intron-1 transcript of GHRL gene. The initial form of each peptide contains a N-terminal signal peptide that is cleaved by signal peptidase in the
endoplasmic reticulum and gives rise to proghrelin, exon 3-deleted proghrelin, and pro-In1-ghrelin. By further post-translational processing, proghrelin is cleaved to
produce different peptides.
activation of GHS-R1a, a Gq protein-coupled phospholipase-
3/inositol-3-phosphate signaling mediates calcium release from
endoplasmic reticulum (9). GHSR1b is a truncated splice
variant. Although the exact function of GHS-R1b is yet to
be described, it may modulate GHS-R1a signaling by forming
GHS-R1a/R1b heterodimers (25, 26). It is also believed to
prevent GHSR1a transfer from endoplasmic reticulum and
regulate its expression on the cell surface (25). Despite
diverse physiologic and pathologic functions proposed so far
for des-acylated ghrelin, its cognate receptor remains to be
discovered (16, 27).
Regulation of fat metabolism, gut motility, secretion of gastric
acid, and modulation of sleep are among paracrine biological
effects (28–30). Modulation of appetite (30), anti-inflammatory
effects (31), and regulating endocrine function constitute main
systemic effects. Given these effects, ghrelin can potentially
contribute to cancer development and behavior. Proliferative
roles of ghrelin have been studied in hepatoma (32), leukemia
(33), colorectal (34, 35), pancreas (4), prostate (36), and breast
(11, 12) tumor cell lines, mainly through mechanisms other than
ghrelin-growth hormone axis. Ghrelin also promoted migration
and invasion in gastric (37) and pancreatic adenocarcinoma
(38) via GHSR/NF-kB and GHSR/PI3K/Akt signaling pathways,
respectively. Likewise, ghrelin inhibition significantly blocked
the migration and invasion of human colon cancer cell lines
(35). Furthermore, ghrelin could augment angiogenesis via ERK2
signaling pathway (39).
Chronic and local inflammation are linked to tumorigenesis
and cancer progression (40, 41). Therefore, ghrelin can be
linked to cancer through its anti-inflammatory effects. Ghrelin
administration significantly retarded inflammation-associated
colon carcinogenesis (42). Furthermore, exogenous ghrelin
hampered systemic inflammatory response in esophageal cancer
patients (43).
Other reports indicate the controversial attribution of both
local and systemic effects of ghrelin to cancer biology. Exogenous
ghrelin had neutral effects on proliferation and invasion of
some cancer cell lines. Likewise, ghrelin was not associated with
prognosis of lung cancer (44) or aggressiveness of esophageal
cancer (45).
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Beside controversies in ghrelin contribution to different
cancers, inconsistencies exist between local in-vitro and summary
clinical effects of ghrelin on the same type of cancer. Although
higher blood ghrelin was associated with decreased incidence of
colorectal cancer (46), higher local ghrelin expression in tumor
tissue correlated with more aggressive tumors (35). Likewise,
although in-vitro studies reported stimulatory effects of ghrelin
on proliferation and invasion of gastric cancer cell lines (37, 47),
the clinical studies linked ghrelin to a reduced incidence (48, 49),
and better prognosis (50). Finally, inconsistencies even exist in
the prognostic roles of serum ghrelin measured before or after
gastrectomy (50).
Several authors have attempted to summarize ghrelin
attributions to cancer (28, 51–57). A review focused mainly
on local effects and expression of ghrelin in different types of
cancers (52). The majority of studies showed the carcinogenic
effects of ghrelin on cancer cell-lines. Clinical studies reporting
prognostic/therapeutic roles of ghrelin were not included.
Another review focused only on human and animal studies.
In-vitro studies were excluded. These studies showed a null or
inverse association between ghrelin and risk/progression of most
cancers (53), highlighting controversies between their conclusion
and previous reviews. A more recent review included data from
in-vitro and clinical studies as well as The Cancer Genome Atlas
(TCGA) to investigate the role of ghrelin and its receptor in
cancer (22). The authors underscored differential expression of
ghrelin receptors as a potential explanation for the controversial
role of ghrelin in different cancers.
A comprehensive consideration of in-vitro and systemic
effects of ghrelin in cancer is missing from previous reviews.
These also did not provide explanations for apparent
controversies between in-vitro studies on different cancers,
as well as between in-vitro and clinical studies of the
same type of cancer. Finally, they did not delineate the
effects of ghrelin on carcinogenesis and prognosis. We
considered specific approaches in this review to address
these inconsistencies.
BREAST CANCER
Attribution of Ghrelin Axis to Cancer
Pathogenesis and Differentiation
Expression of Native Ghrelin Peptide
Among 144 patients with invasive breast cancer, 88.2% had
ghrelin positive tumor cells (Table 1; Supplementary Table 1).
Expression of ghrelin was linked to estrogen receptor (ER) status,
but not to the status of progesterone receptor (PR) andHER2/neu
receptors (96). Authors reported an inverse association of ghrelin
expression with tumor size, tumor grade, and expression of the
proliferation marker Ki-67. Similarly, 81.2% of 197 male patients
with breast cancer had ghrelin positive tumor cells. The intensity
of ghrelin staining was not uniform in different parts within
a tumor, suggesting a shift from production of native ghrelin
to other variants of ghrelin in malignant conditions (97). Non-
malignant breast tissue expressed no ghrelin (58), or lower levels
of ghrelin compared to malignant tissue (11). Quantification of
ghrelin at transcript level did not show a significant difference
between normal and malignant breast tissues (12).
Expression of Ghrelin Receptor
GHSR1b expression was detected in breast cancer cell lines
(11, 12). However, the majority of in-vitro studies did not report
GHSR1a expression (12, 29). Similarly, GHSR1b was highly
expressed in breast malignant tissues, while it was not present in
normal mammary tissue (11, 12). Studies have shown low levels
of GHSR1a expression in both normal and malignant breast
tissues. However, studies have come to different conclusions
with regards to the difference between GHSR1a expression in
normal andmalignant tissues. One study reported lower GHSR1a
expression in cancerous tissue compared to non-cancerous tissue
(58); however, the difference was non-significant in another
study (12). The differential expression of GHSR1b in normal
and malignant breast tissues implies its probable role in breast
cancer pathophysiology.
Expression of Variant Ghrelin Peptides
Ghrelin gene produces heterogeneous peptide variants. Full-
length and exon 3-deleted pre-proghrelin was transcribed both
in benign, MCF-10A, and malignant breast cancer cell lines,
MDA-MB-231,MCF-7,MDA-MB-435, and T47D.Unlike similar
expression levels of full-length pre-proghrelin between benign
and malignant cell lines, exon 3-deleted preproghrelin mRNA
was significantly more abundant in some malignant cell lines
(MDA-MB-231 and MDA-MB-435 but not MCF-7) compared to
a benign cell line (11). Similarly, exon 3-deleted preproghrelin
showed more intense expression in cancerous compared to
normal breast tissues. Staining became more intense in tissue
sections of tumors with higher grades (11).
In1-ghrelin variant retains the copy of intron-1 in the
expression of ghrelin gene. In1-ghrelin expression was
higher in the invasive breast cancer cell-line, MDA-MB-
231, compared to non-invasive MCF-7 breast cancer cell
line (59). Similarly, expression of In1-ghrelin was 8-fold
upregulated in high-grade breast tumor samples relative to
normal tissues. Expression of this variant was highly correlated
with proliferation and mitotic markers, Ki-67 and cyclin
D3. GHSR1a and GHSR1b expressions were significantly
correlated with In1-ghrelin level, while none of these receptors
correlated with native ghrelin expression (12). In1-ghrelin
expression was not linked to ER, PR, and HER2/neu status
(positive correlation between HER2/neu and In1-ghrelin
expressions was not statistically significant). Augmented
expressions of exon 3-deleted ghrelin and In1-ghrelin in
breast cancer may indicate the importance of these peptides in
cancer pathophysiology.
Some evidence showed opposite regulation of ghrelin and In1-
ghrelin. Although ghrelin, des-acylated ghrelin and Tamoxifen
upregulated ghrelin expression in the malignant cell line, they
reduced In1-ghrelin expression. Because these effects were not
seen by estradiol, authors postulated that Tamoxifen affects
ghrelin expression by an ER-independent manner (12).
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TABLE 1 | Summary of in-vitro, in-vivo, and clinical data concerning the expression of ghrelin-axis in different types of cancer.
Ghrelin GHSR-1a GHSR-1b Other References
mRNA Local protein level Blood/cell culture
media protein
concentration
mRNA Protein mRNA Protein
Breast cancer
Cancer cell lines
T47D pG +, ex 3-del + –, + + (11, 29)
MDA-MB231 pG +, ex 3-del +,
native –, In-1 +,
–, +, – +, + GOAT + (11, 12, 29)
MCF7 pG +, ex 3-del + –, + + (11, 29)
MB-435 pG +, ex 3-del + –, + + (11)
Human samples
Normal Native +, In-1 + Native –, aG +, ex
3-del +,
+ ++, + – – GOAT + (11, 12, 58)
Benign Native – + (58)
Carcinoma Native +, In-1 ++,
In-1 +





+ +, + + + GOAT ++ (11, 12, 58–61)
Colorectal cancer
Human samples












AGS Native – +, +* + (37, 47)
SGC7901 ++ * (37)
Human samples











Normal > SCC (total)
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TABLE 1 | Continued
Ghrelin GHSR-1a GHSR-1b Other References
mRNA Local protein level Blood/cell culture
media protein
concentration
mRNA Protein mRNA Protein


















Native + Native – – (75)
Human samples
SCLC SCLC = normal




NSCLC > normal (2)
(44, 76)
NSCLC + (44, 76, 77)
Adenocarcinoma Native + Native – – (75)
SCC Native + Native – + (75)
Neuroendocrine Native + Native + + (75)
Prostate cancer
Cancer cell-lines
DU145 Native ++, native –,
native +, In-1 +
Native – Native – +, + +, + (78–80)
LNCaP Native +, native –,
aG +, ex 3-del +,
native ++, In−1 +
Native – Native – +, – +, – (36, 78–80)
PC3 Native + (3), aG ++,
ex 3-del ++, In-1
++
Native – +, – ++, – (36, 78–80)
ALVA41 Native +, In-1 + ++ + (78, 79)
22Rv1 Native +, In-1 + + + (78, 79)
VCaP Native +, In-1 + (79)
Normal cell line Native –, native +,
In-1+
+ – (78, 79)
(Continued)
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TABLE 1 | Continued
Ghrelin GHSR-1a GHSR-1b Other References
mRNA Local protein level Blood/cell culture
media protein
concentration
mRNA Protein mRNA Protein
Human samples









Benign Native + Native –, Native +,
ex 3-del +
+ (36, 80)
Carcinoma Native + (2), In-1
++
native –, native ++,
ex 3-del ++






PANC1 Native + Native – + + + + (38)
MIAPaCa2 Native – Native – + + + + (38)
BxPC3 Native – Native – + + + + (38)






Native + Native + +* +* (68, 84)
Clear cell subtype of renal cell carcinoma (ccRCC)
Cancer cell-lines
786-0 Native ++ + (85)
ACHN Native + + (85)
A-498 Native + + (85)
769-P Native + ++ (85)
A-704 Native + + (85)
Human samples
Normal Native + (85)
Carcinoma Native ++ (85)





Native + Native + Native+ + + (86)
Glioma: C6 (rat),
U251(human)
+ + + + (87)
(Continued)
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TABLE 1 | Continued
Ghrelin GHSR-1a GHSR-1b Other References
mRNA Local protein level Blood/cell culture
media protein
concentration
mRNA Protein mRNA Protein
Normal astrocytes Native –/+ Native –/+ Native –/+ –/+ –/+ (86)
Human samples
Glioblastom Native (38/39) + (38/39) (88)
Anaplastic
astrocytoma
Native (12/13) + (5/13) (88)













Normal Native + + (92)
Cancer Native + (2) + (92, 93)
Oral squamous cell carcinoma
Cancer cell lines
BHY Native + ++ + (94)
HN Native ++ + ++ (94)
Human samples
Normal Normal > cancer (95)
Cancer
mRNA: messenger RNA; pG: pre-proghrelin; native: naturally occurring mature ghrelin; daG, des-acylated ghrelin; aG, acylated ghrelin; GHS-R, ghrelin hormone receptor; In-1: intron-
1 ghrelin; ex 3-del: exon 3-deleted ghrelin; GOAT: Ghrelin-O-Acyltransferase; GHROS LncRNA: ghrelin opposite strand long non-coding RNA; EGJA: esophago-gastric junctional
adenocarcinoma; SCC: squamous cell carcinoma; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; CADS: cancer-associated dyspepsia syndrome.
+: positive expression; –: negative expression; –/+: equivocal expression; number of + indicate relative expression.
*type of ghrelin receptor not specified in corresponding reference.
Number in parenthesis indicate number of references supporting corresponding data. Numbers in format of x/y indicate number of sample size in corresponding reference with
positive results.
Commas separate data of different references in case of each parameter.
Circulating Ghrelin Level
We know little about levels and clinicopathologic roles of
circulating ghrelin in breast cancer patients (60, 61, 98).
A case-control study reported comparable circulating
ghrelin levels in hereditary breast cancer patients (n =
25) and their healthy relative controls (n = 38) (98).
More research on circulating ghrelin in breast cancer
is warranted.
Expression of Ghrelin Processing Enzyme
High expression of GOAT was detected in MDA-MB-231 cancer
cell line (12). Furthermore, it was upregulated inmalignant breast
Frontiers in Oncology | www.frontiersin.org 8 October 2019 | Volume 9 | Article 1014
Soleyman-Jahi et al. Attribution of Ghrelin to Cancer
tissues. GOAT expression was correlated with the expression of
In1-ghrelin variant to support the assumption that In1-ghrelin
might be the main substrate for GOAT (12).
Exogenous Native and Variant Ghrelin Peptide
Treatment by higher doses of both acylated ghrelin and des-
acylated ghrelin inhibited proliferation of MCF-7 cancer cell line
(29). The inhibitory effect on MDA-MB-231 was only seen by
acylated ghrelin treatment. In contrast, treatment by lower doses
of acylated ghrelin enhanced proliferation rates of some breast
cell lines, MDA-MB-231 and MDA-MB-435, but not MCF-7 and
normal MCF-10A (11, 59). A similar differential pattern was
reported for exon 3-deleted pre-proghrelin mRNA among cell
lines (11), implying a role for this ghrelin variant in the response
of cancer cells to exogenous native ghrelin. Both In1-ghrelin
peptide treatment and its transfection into MDA-MB-231 and
MCF-7 breast cancer cell-lines increased proliferation, migration,
and sphere-formation (12, 59). These effects accompanied
upregulation of TGF-β1, JAG1, and β-catenin expression (59).
Differences in type and dose of exogenous ghrelin and type of
cell line used could explain these different observations.
Ghrelin and Ghrelin Receptor Genes Polymorphism
In a nested case-control study (648 cases/659 controls), none of
the tagging single-nucleotide polymorphisms (SNP) in theGHRL
gene were associated with the risk of breast cancer development
(99). However, another nested case-control (1,359 cases/2,389
controls) reported associations of some polymorphisms (GHRL
rs171407-G allele and GHSR 2948694-GG genotype) with
increased risk of breast cancer (100). Finally, associations of
Gly57Gly SNP of GHSR with increased risk, and association of
some rare haplotypes of GHRL with reduced risk of breast cancer
were reported. Authors did not find altered risk with individual
SNPs of GHRL (101). Differences in distribution of breast cancer
subtypes, sample size, ethnicity, and age of the study populations
could explain controversial results.
Attribution of Ghrelin Axis to Summary
Clinical Survival
Expression of Ghrelin Peptides and Receptor
Positive ghrelin immune-reactivity of tumor tissue associated
with better survival, independently of other putative prognostic
factors such as grade and stage of the tumor (Table 2;
Supplementary Table 1) (96). Likewise, ghrelin expression was
associated with favorable breast cancer-specific survival in male
breast cancer patients, irrespective of primary tumor size and
lymph node involvement. Ghrelin status did not affect response
to adjuvant endocrine therapy among ER-positive cases (97).
Further, ghrelin positivity of tumor cells was associated with a
decreased mortality when comparing 190 patients who died of
breast cancer and 190 breast cancer patients as living controls
(127). These findings are in line with findings of inverse
associations between native ghrelin expression and proliferation,
size, and grade of breast tumor cells (96). In contrast, higher
expressions of In1-ghrelin associated with shorter disease-free
survival in 117 cases of grade three breast cancer (59).
Ghrelin and Ghrelin Receptor Genes Polymorphism
Polymorphism of GHRL gene was linked to both all-cause and
breast cancer-specific mortalities. GHRL rs27647-GG genotype
was correlated with worse all-cause mortality, whereas GHRL
rs3755777-C allele conferred overall survival advantage (102).
Future studies can explore if these polymorphisms alter
expression of ghrelin peptide and receptors.
COLORECTAL CANCER
Attribution of Ghrelin Axis to Cancer
Pathogenesis and Differentiation
Expression of Native Ghrelin Peptide
Both normal and malignant human colon cell lines express
ghrelin (Table 1; Supplementary Table 2). Expression of ghrelin
is upregulated in malignant compared to normal cell lines and
in cancerous compared to adjacent normal tissue samples taken
from cancer patients. Immune-reactivity to ghrelin was stronger
in samples from higher stage tumors. A similar correlation was
observed between ghrelin expression and tumor grade. However,
poorly differentiated tumors demonstrated dramatic reductions
in immune-reactivity to ghrelin. It potentially rules out a limiting
dependency of cancer cells on tumor-produced ghrelin as they
still survive even when ghrelin expression is lost in high grade
tumors (35).
Expression of Ghrelin Receptor
GHSR1a and GHSR1b were present in both normal and
malignant cell lines. However, malignant cell lines expressed
higher GHSR1b. With the increasing stage of cancer patients,
tumor expression of GHSR1a and GHSR1b decreased and
increased, respectively (35). Alterations of ghrelin receptor
expressions are in line with breast cancer, implying a more
important role of GHSR1b in cancer biology.
Circulating Ghrelin Level
In a nested case-control (523 cases/523 controls) of male
smokers, colorectal cancer incidence was higher in subjects
within the lowest quartile compared to those within the highest
quartile of serum total ghrelin before cancer occurrence. This
was the case for patients with their cancer diagnosed within
10 years of blood draw; however, patients with diagnosed after
20 years of blood draw showed a positive association between
serum total ghrelin and colorectal cancer risk (46). No association
was reported for the 10–20-year interval group. Another nested
case-control (60 cases/60 controls) did not show an association
between cancer risk and blood ghrelin level sampled ≤5 or 10–
20 years before cancer diagnosis. Furthermore, there was not
significant within-individual changes in ghrelin level during the
time considered (113).
Two studies reported lower levels of ghrelin in colorectal
cancer patients than healthy control subjects (62, 63). Serum
ghrelin level showed an inverse association with tumor stage
and was higher in patients with anti-Helicobacter pylori Ab.
Despite inverse association of ghrelin with BMI in healthy
controls, no such correlation was reported in cancer patients
(62). Conversely, another study reported higher serum total
ghrelin in cancer patients (patients with BMI more than 30 and































TABLE 2 | Summary of in-vitro, in-vivo, and clinical data concerning the role of ghrelin-axis in development and progression of different types of cancer.
Breast cancer Gastric cancer
In-vitro Clinical In-vitro In-vivo Clinical
MDA-MB231 MCF-7 MB-435 Carcinoma AGS GES-1 SGC7901 Adenocarcinoma
Cell viability
Proliferation:
By aG: ↓, ↑




























Ghrl haplotypes GGAC and GGAT ↓
Ghsr SNP Gly57Gly ↑
Ghrl rs171407-G allele ↑
Ghsr rs2948694-GG genotype ↑
Plasma ghrelin↔
Progression:
Lymph node involvement: Tissue GHS-R1a
peptide ↓, In-1 gene expression ↑
Grade: Tissue ex 3-del ghrelin peptide ↑
Survival: Tissue ghrelin peptide level ↑ (3),
Ghrl rs27647-GG SNP ↓,
Ghrl rs3755777-C SNP ↑,






















Serum total ghrelin ↓
Progression:
Grade: plasma total ghrelin↑, ↓
Survival: pre-operative
plasma ghrelin and aG
biphasic, post-operative
plasma ghrelin ↑
(11, 12, 29, 59) (11, 29, 59) (11) (11, 96–103) (37, 47) (37, 104) (37) (65, 67) (50) (105)
Oesophageal cancer Pancrease cancer
In-vitro Clinical In-vitro In-vivo Clinical





























SIRS durations: ghrelin IV
infusion ↓




Serum total ghrelin ↓ (2)
Progression:
Stage: tumor tissue ghrelin ↑ (2)
Invasion: tumor tissue ghrelin ↑
Grade: tumor tissue ghrelin ↓
Venous invasion: tumor tissue
ghrelin ↑























































































































TABLE 2 | Continued
Colorectal cancer
In-vitro In-vivo Clinical






















IL-6, TNF-α, IFN-γ :aG↔
Peptide level









Ghrl rs27647-T allele ↓, Ghrl rs35683-C allele ↓ (Czech)
Ghrl rs27647-T allele↔, Ghrl rs35683-C allele↔ (Germany)
Serum total ghrelin: overall risk↓, risk in <5 years of blood draw↔,
risk in <10 years of blood draw ↓, risk in 10–20 years of blood draw ↔
(2), risk in >20 years of blood draw ↑
Progression:
Stage: serum total ghrelin↓, plasma ghrelin↑,
tumor tissue ghrelin↑, tumor tissue GHS-R1a ↓,
tumor tissue GHS-R1b ↑
Tumor size: plasma ghrelin↑
Tumor Grade: plasma ghrelin↑
Survival: plasma ghrelin↔, GHRLOS LncRNA↓
Lymph node involvement: GHRLOS LncRNA↓




















































































Survival: plasma Ghrelin↔ (2)
GHS-R agonist↔ (2)
Lean body mass: GHS-R agonist
↑ (2),↔
Body weight: GHS-R agonist ↑ (2)
Appetite: GHS-R agonist ↑

























































































TABLE 2 | Continued
Prostate cancer
In-vitro In-vivo Clinical





































Tumor volume: daG↔, GHSR
antagonist ↓
In-1 transfection > aG transfection
Tumor weight: GHSR antagonist ↓
Tumor Ki67: daG↔, GHSR antagonist
↔
Tumor CD31: daG:↔
Tumor EGFR: GHSR antagonist ↓
Cancer development/progression
Progression:
Gleason score: plasma GOAT ↑
Metastasis: plasma GOAT ↑
Progression markers: In-1 gene
expression↑,
ghrelin gene expression↔
(78, 80) (36, 78, 80) (36, 79, 80, 124) (78) (78) (78) (78, 124, 125) (78, 83)
Clear cell subtype of renal cell carcinoma Oral squamous cell carcinoma
In-vitro In-vivo Clinical In-vitro Clinical
786-0 ACHN A-498 Cancer cell-line panel 786-0 Carcinoma BHY HN Cancer
Cell invasion/migration
By ghrelin: ↑






Number of metastatic lung
nodule: ghrelin gene knocked out
mice < ghrelin naïve mice
Cancer development/progression
Progression:
Tumor progression: ghrelin ↑
Survival: ghrelin ↓ (2)
Cell viability
Proliferation:





Grade: tumor ghrelin ↓
(85) (126) (85) (85) (94) (95)





















Tumor cell proliferation: Ghrelin/ GHS-R1a ↑ (in
anaplastic astrocytoma and glioblastomas)




Tumor size: tumor GHSR
expression ↑































































































































































































































































































































































































































































































































































































































































































































































































































































































































<16 were excluded). Ghrelin level was higher in patients with
larger tumor size, higher stage, and higher grade. No association
between ghrelin and patients‘ BMI was reported (64). Waseem
et al. showed that serum ghrelin was higher in cachectic cancer
patients compared to non-cachectic patients, which could be
a compensatory response to devastating metabolic conditions.
Additionally, ghrelin levels were not correlated with stage, grade,
and BMI (35). Different BMI distribution of cases includes in
each study might explain some of controversy.
Long Non-coding Ribonucleic Acids (LncRNA)
The LncRNA GHRLOS is transcribed from the antisense strand
of ghrelin gene; however, it is not translated (128). Compared
to adjacent normal tissue, 54.4% (199/366 cancer patients)
of tumor specimens showed reduced GHRLOS transcript.
Downregulation ofGHRLOSwas associated withmore aggressive
tumor phenotype (114).
Exogenous Native Ghrelin
Ghrelin promoted cancer cell proliferation. The pro-proliferative
effect of ghrelin was attenuated by GHSR inhibitor ([D-Lys3]-
GHRP-6), dominant-negative mutation of Ras, PI3K inhibitor
(LY 294002), dominant-negative mutation of Akt, or mTOR
inhibitor (rapamycin). These findings imply the functional role
of Ras/PI3K/Akt/mTOR pathway in ghrelin-induced cancer cell
proliferation (34).
In a mouse model of inflammation-associated colorectal
carcinogenesis induced by Azoxymethane/Dextran Sodium
Sulfate (AOM/DSS), exogenous ghrelin treatment reduced tumor
burden and increased body weight. Ghrelin administration
resulted in reduced infiltration of macrophages and neutrophils
in ulcerated colon tissue. In contrast, Ghrelin treatment did
not alter tumor incidence or size in APC-mutant mice (42) or
colon-26 tumor bearing mice (111, 112).
Exogenous Ghrelin Inhibitors
Either GHSR antagonist or neutralizing anti-ghrelin Ab
diminished proliferation and invasion of malignant cell lines
(35). In the AOM/DSS model, the number of tumors was not
different between Ghrl-deleted mice and naïve mice. However,
Ghrl-deleted mice had larger tumors. The proliferation,
apoptosis, and angiogenesis indices did not show a difference
between groups. In APC-mutant mice, the deletion of ghrelin
gene did not affect the size or number of tumors (42). These
findings suggest tumor-suppression by anti-inflammatory
effects of systemic ghrelin, which is more pronounced in
exogenous ghrelin.
Ghrelin and Ghrelin Receptor Genes Polymorphism
GHRL rs27647-T and rs35683-C alleles were associated with
decreased risk of colorectal cancer in Czech Republic (680
cases/593 controls), but not German (569 cases/726 controls),
population (115).
Attribution of Ghrelin Axis to Summary
Clinical Survival
After adjusting for its association with tumor stage, serum
total ghrelin was not correlated with survival (Table 2;
Supplementary Table 2) (64). Low levels of LncRNA GHRLOS
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in tumor samples of cancer patients were associated with a
shorter survival (114). Evaluation of prognostic roles of pre- and
post-surgical circulating ghrelin can provide clues about specific
roles of local and systemic ghrelin in colorectal cancer (64).
Implications of Ghrelin Axis in Cancer
Therapy
GHSR agonists, HM01 and Z505 Hydrochloride, showed
beneficial effects on cachexia in mouse models of colon cancer.
However, the treatment did not alter tumor weight (84, 106).
GASTRIC CANCER
Attribution of Ghrelin Axis to Cancer
Pathogenesis and Differentiation
Expression of Native Ghrelin Peptide
Ghrelin was not expressed in the AGS cell line (Table 1;
Supplementary Table 3) (47). Compared to normal tissue, tumor
tissue expressed negligible amount of ghrelin (65, 66). The low
level of ghrelin in tumor tissue suggests impairment of ghrelin
production in damaged gastric mucosa. However, there was no
association of local ghrelin expression with the extension and
location of the tumor (65).
Expression of Ghrelin Receptor
Ghrelin receptor is up-regulated in malignant cell lines (37, 47)
and tumor tissue (66). AGS cells expressed both GHS-R1a and
GHS-R1b (47) and GHS-R expression was higher in SGC7901
compared to AGS (37).
Circulating Ghrelin Level
Plasma ghrelin was lowest in 23GC patients compared to patients
with benign conditions, such as acute gastritis or gastric ulcer
(67). Likewise, GC patients associated with H. pylori infection
had low ghrelin levels. Authors suggested plasma ghrelin in GC
is influenced by the extent of the tumor and H. pylori-induced
atrophic gastritis. Plasma ghrelin drops significantly after total
gastrectomy (50, 65), showing the stomach as the main source
of ghrelin. Blood ghrelin recovered to some extent thereafter,
suggesting compensatory production of ghrelin from other non-
gastric organs (65). No difference was observed in serum ghrelin
between healthy cases and patients with gastric neuroendocrine
tumor (68).
In a nested case–control (261 non-cardia GC/441 control)
(49), risk of non-cardia GC was higher for those in the lowest
quartile of serum ghrelin compared vs. highest quartile. The
association could be due to atrophic gastritis as a reason
for both lower ghrelin and higher risk of cancer. Authors
also considered anti-inflammatory effects of ghrelin as another
possible mechanism. Likewise, inverse association of serum total
ghrelin with risk of non-cardia and cardia GC adjusted for
potential confounders was reported (48). Potential use of ghrelin
in identifying early GC can be explored.
Patients with undifferentiated adenocarcinoma had higher
plasma ghrelin compared to those with differentiated tumor
(67). Similarly, undifferentiated tumor tissue expressed higher
ghrelin than differentiated tumor tissue (65). No association was
reported between ghrelin and other clinicopathological factors
(e.g., tumor stage).
Exogenous Native Ghrelin Peptides
Both ghrelin and des-acylated ghrelin induced proliferation
of adenocarcinoma AGS cells via activation of the ERK1/2
and PI3K/Akt pathway (47, 104). Different concentrations
of ghrelin and des-acylated ghrelin could increase cells in
the S phase of the cell cycle. Furthermore, ghrelin could
promote proliferation, migration, and invasion of AGS
and SGC7901 cells via GHS-R/NF-jB signaling pathway
(37). Ghrelin promoted CDK6 expression, suppressed P53
expression, and upregulated the metastasis factor MMP2
expression. Likewise, ghrelin administration increased tumor size
in mice.
Attribution of Ghrelin Axis to Summary
Clinical Survival
Circulating Ghrelin Level
Higher post-operative plasma ghrelin was linked with better
prognosis in GC patients (Table 2; Supplementary Table 3)
(50, 105). This survival advantage was independent of stage,
grade, cachexia, and tumor size or location. However, the pre-
operative plasma ghrelin showed a different prognostic pattern
(50). Patients with either the lowest or highest quartile of
plasma ghrelin showed higher survival rates than patients with
second-third quartiles. The difference in prognostic patterns
of pre-operative and post-operative plasma ghrelin supports
the interaction between opposite local and systemic effects
of ghrelin in determining the final summary effect. The
unfavorable paracrine effects of ghrelin play some role when
tumor cells are still exposed to local ghrelin before gastrectomy.
However, the prognostic pattern of post-operative blood ghrelin,
wherein tumor cells are no longer exposed to local ghrelin,
was purely dominated by protective systemic effect. Therefore,
ghrelin could be considered a promising prognostic biomarker
and therapeutic option in GC like other novel candidates
introduced (129, 130).
OESOPHAGEAL CANCER
Attribution of Ghrelin Axis to Cancer
Pathogenesis and Differentiation
Expression of Native Ghrelin Peptide
Ghrelin expression was negligible in tumor specimens of
esophageal adenocarcinoma (OA) (70). However, high ghrelin
expression was observed in 29.0% of patients with squamous cell
carcinoma (OSCC) (107) that was associated with depth of tumor
invasion and grade (Tables 1, 2; Supplementary Table 4).
Expression of Ghrelin Receptor
GHSR1a gene expression was higher in biopsies from Barrett’s
esophagus compared to normal squamous epithelium tissue (69).
Circulating Ghrelin Level
Individuals with low serum ghrelin had 5-fold and 7-fold higher
risks of esophagogastric junctional adenocarcinoma (OGJA) and
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OSCC, respectively (49, 72). Authors attributed this association
to the presence of atrophic gastritis. A population-based study on
OSCC cancer reported similar findings (48). The association was
independent of atrophic gastritis markers. Therefore, they argued
the role of atrophic gastritis in ghrelin-cancer risk association. A
strong inverse association between serum ghrelin and risk of OA
cancer was also reported (71). This association was restricted to
overweight patients. Authors contributed this inverse association
to anti-inflammatory effects of ghrelin. In contrast, a case-
control reported no association between serum ghrelin and risk
of OA (48).
Post-operative plasma ghrelin was lower than the pre-
operative concentrations in esophageal cancer patients, which
slightly recovered in 6–24 months. There was no relationship
between circulating ghrelin and clinicopathologic features of
tumor (45, 108).
Exogenous Native Ghrelin Peptides
Treatment of OE-19 cell line with different concentrations of
ghrelin revealed an inhibitory effect on Barrett’s carcinogenesis
via anti-inflammatory mechanism (69). Ghrelin attenuated the
level of TNFa-induced COX-2 and IL-1b expression. Likewise,
exogenous ghrelin was safe and reduced post-operative systemic
inflammation (duration and intensity) in esophageal cancer
patients (43).
Ghrelin and Ghrelin Receptor Genes Polymorphism
An Australian case-control (260 OA/301 OGJA/213 OSCC
cases/1,352 controls) revealed no major association between
ghrelin gene SNPs and cancer incidence. A modest positive
association between rs696217 SNP and OA cancer was reported
in cases with BMI< 25 kg/m2 (70).
Attribution of Ghrelin Axis to Summary
Clinical Survival
Expression of Native Ghrelin Peptide
A trend of worse 1-year survival was reported in cancer patients
positive vs. negative for local tumor expression of ghrelin
(Table 2; Supplementary Table 4) (107). This finding was in
line with the association of local ghrelin with tumor invasion.
The 5-year survival rates showed no difference. Because local
and systemic ghrelin exert opposite effects in esophageal cancer,
investigating the prognostic role of circulating ghrelin will be
more elucidative.
LUNG CANCER
Attribution of Ghrelin Axis to Cancer
Pathogenesis and Differentiation
Expression of Native Ghrelin Peptide and Its
Receptor
Expression of ghrelin and its receptors seems to be
linked to the histological subtype of lung cancer (Table 2;
Supplementary Table 5). Ghrelin and GHSR1a are more
abundantly expressed in tumors of neuroendocrine origins
compared to those of non-endocrine origins (73, 75). Only one
study reported expression of GHSR1b in non-small cell lung
carcinoma (131). To our knowledge, expression of GHSR1b
has not been investigated in other subtypes of lung cancer.
Furthermore, GHSR expression was linked to the activation of
the MAPK/ERK and PI3K/AKT signaling and accompanied
cell proliferation in Gefitinib (epidermal growth factor tyrosine
kinase inhibitor)-resistant non-small cell lung cancer cell
lines (74).
Circulating Ghrelin Level
Alterations of serum ghrelin in patients with lung cancer
is most probably related to tumor-driven systemic catabolic
and inflammatory state. Two studies reported higher levels
of circulating ghrelin in cancer patients compared to healthy
controls (44, 77). Ghrelin level was not associated with stage
and histological subtype of tumor. The association of ghrelin
with body weight loss (BWL) was conflicting. This could have
been due to different definitions of BWL in two studies. The
study that reported positive association of ghrelin with BWL used
higher cut-off (10 vs. 5%) for weight loss definition (77). Ghrelin
level was even higher in cancer patients with BWL compared to
cancer patients without BWL (77). Another study on a smaller
sample size reported comparable plasma levels of ghrelin between
cancer patients and healthy controls. Yet, patients with cachexia
had higher levels of plasma ghrelin compared to non-cachectic
patients (76).
Exogenous Native Ghrelin
Ghrelin had differential effects on lung cancer cell lines, some
of which could be explained by their origin (endocrine vs.
non-endocrine) and subtype. Ghrelin treatment did not affect
cell proliferation in CALU-1 cancer cell line (non-endocrine
origin) (73). Similarly, in-vitro administration of ghrelin did
not significantly change viability, proliferation, apoptosis, and
cellular respiration in HLC-1 lung adenocarcinoma cell line
(non-endocrine) (99). In contrast, enhanced proliferation of
A549 lung adenocarcinoma cell line upon ghrelin treatment
was recently reported. The ghrelin effect on proliferation was
mediated by GHSR and at least two independent intracellular
signaling pathways, including PI3K/Akt/mTOR/P70S6K and
ERK molecules, were involved in the process (117). Finally,
GHSR antagonist attenuated cell proliferation associated with
MAPK/ERK and PI3K/AKT signaling in Gefitinib-resistant non-
small cell lung cancer cell lines (74).
Both ghrelin and des-acylated ghrelin inhibited proliferation
of H345 small cell lung carcinoma cell line (neuro-endocrine).
GHSR1a and GHSR1b mRNA were not detected by RT-PCR in
this cell-line. Absence of expression of known ghrelin receptors
may indicate existence of other modes of action for ghrelin.
Co-administration of ghrelin with a tyrosine phosphatase
inhibitor abolished ghrelin anti-proliferative effects on H345
cells, indicating that dephosphorylation could be a crucial step in
the signaling pathway(s) underlying inhibitory effects of ghrelin
on this cell line. Ghrelin activated apoptosis pathway could
also explain growth-modulating effects of ghrelin on H345 cell-
line (75).
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Attribution of Ghrelin Axis to Summary
Clinical Survival
Two studies reported no associations between ghrelin level and
overall survival in cancer patients (44, 77). Ghrelin was not
associated with tumor response to therapy, either (44).
Implications of Ghrelin Axis in Cancer
Therapy
Ghrelin administration alleviated tumor-induced cachectic
conditions in mouse models of Lewis lung carcinoma and
adenocarcinoma (118, 119). Although ghrelin treatment did
not change tumor mass, it improved survivals of Lewis lung
carcinoma mice (119). This survival advantage could be due to
an improvement in cachexia, but doesn’t have a direct effect
on tumor.
Anamorelin, a ghrelin receptor agonist, has been studied
for the treatment of cachexia in patients with non-small cell
lung cancer (120–123). Phase 3 clinical trials ROMANA 1
and 2 (overall 977 patients) showed that the administration of
Anamorelin was effective in increasing body weight in cancer
patients with cachexia. However, it did not alter median survival
over 1 year (120).
In conclusion, ghrelin alteration in patients with lung
cancer seems to be a secondary systemic response to cancer-
induced cachexia (Table 2). Current evidence does not support
a link between ghrelin and survival of lung cancer patients.
Derived from both in-vitro and clinical studies, direct effects
of ghrelin on lung carcinoma may be varied based on
subtype of tumor. Hence, it is suggested for future studies
to evaluate segregated contributions of ghrelin to pathogenesis
and prognosis of lung cancer patients based on the origin




Normal prostate cell line expresses In1-ghrelin and GHSR1-
a. GHSR1-b is not expressed and the expression of ghrelin is
deemed controversial (78, 79). Cancer cell lines consistently
express acylated ghrelin, In1-ghrelin, and exon 3-deleted ghrelin.
However, the expressions of ghrelin, GHSR1-a, and GHSR1-b are
controversial (36, 78–80) (Tables 1, 2; Supplementary Table 6).
Although acylated ghrelin treatment stimulated PC3 and LNCaP
proliferation via MAPK/ERK1&2 pathway at the concentration
of 10 nM, this effect was not observed for treatment by
exon 3-deleted (36). Treatment with In1-ghrelin consistently
increases proliferation of both the normal and the cancer cell
lines studied. Other studies reported controversial results for
ghrelin and ghrelin receptor expression as well as effects of
exogenous ghrelin or acylated ghrelin on cancer cell proliferation
(36, 78–80). Some of these contradictions can be explained
by the different type of cell line studied and the different
dose of exogenous ghrelin used. In the study that investigated
endogenous expression and exogenous effects of both native
and In1 variant ghrelins in different prostate cancer cell
lines, tumor xenograft, and human tumor samples, In1-ghrelin
showed overall more impactful tumor-promoting and oncogenic
effects (78).
Although administration of des-acylated ghrelin did not affect
tumor volume in mice with PC3 cell xenograft (125), GHSR
antagonist [D-Lys 3]-GHRP-6 reduced the tumor volume (124).
Furthermore, mice with In1-ghrelin transfected PC3 xenograft
presented larger tumor size compared to mice with acylated
ghrelin transfected PC3 xenograft (78).
Serum levels of acylated ghrelin was comparable (78) or
higher in prostate cancer patients, compared to benign prostate
hyperplasia cases (81). No significant differences in serum
levels of total ghrelin have been reported between cancer and
hyperplasia/normal cases. However, In1-ghrelin and GOAT
concentrations are higher in cancer patients compared to normal
cases (78, 80–82). Although ghrelin splice variants are locally
expressed in cancer tissue, ghrelin receptor is not expressed and
the results for the expression of native ghrelin are controversial.
Tumor ghrelin gene expression did not show any association
with tumor progression markers (78); however, plasma GOAT
concentration and tumor In1-ghrelin gene expression were
associated with more aggressive tumor phenotypes (78, 83). In1-
ghrelin and GOAT, but not native ghrelin, show a consistent
unfavorable impact on prostate cancer aggressiveness and the
summary clinical role is dominated by local effects. A recent
review emphasized the role of G-coupled ghrelin receptor in
prostate cancer (132).
Pancreas Cancer
GHSR1a and GHSR1b transcripts and proteins are detectable
in pancreatic adenocarcinoma cell-lines. The highest level
of GHSR1b transcription was seen in PANC1 cell-line.
Ghrelin transcript was slightly expressed in the PANC1
cell-line and absent in other cell-lines (Tables 1, 2 and
Supplementary Table 6). Exogenous ghrelin at 1–10 nM
dose increased proliferation, invasiveness, motility, and Akt
phosphorylation of all cell-lines. These effects were more
pronounced in PANC1 cell-line. Proliferation was suppressed
in 100 nM dose (38). Likewise, a clinical study on patients
with pancreatic neuroendocrine tumors reported local co-
expression of ghrelin and GHSR in cancer tissue resulted in
worse survival (84).
However, administration of systemic ghrelin (30 nM/kg) to
a mouse model transplanted with pancreatic carcinoma cell
line (BALB/c-nu/nu mice injected subcutaneously with MIA-
PaCa2 cell line) led to decreased tumor size compared to
untreated control mouse. Although ghrelin inhibited plasma
leptin levels, it had no effect on body weight (109). It is
debated whether the inhibitory effect observed was due to the
dose of ghrelin administrated being in the inhibitory range,
or due to the dominancy of systemic effects of ghrelin over
local stimulatory effects. Dose escalation of exogenous ghrelin
administered could have helped clarify it. In a potential second
study, this could be an example of controversy between local and
short-term systemic effects of ghrelin on a type of cancer. The
summary long-term clinical role of systemic ghrelin should be
a trade-off between these two contrary effects. Ratio of systemic
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acetylated/total ghrelin showed no significant association with
survival of advanced pancreas cancer patients (110).
Renal Clear Cell Carcinoma (RCC)
A study investigated ghrelin effects on RCC in in-vitro, in-vivo,
and clinical setting. The authors observed higher levels of ghrelin
expression in metastatic RCC and ghrelin-GHS-R axis induced
the invasion in cancer cell (RCC, 786–0, ACHN, A-498, 769-
P, and A-704 human cell lines). This effect was mediated via
GHS-R that induced AKt phosphorylation at Ser473 and Thr308
of PI3K/Akt pathway, which finally led to cell migration at
acylated ghrelin concentrations of 180 nM. Via this pathway,
ghrelin induced Snail expression with subsequent decreased E-
cadherin and accelerated migration. Accordingly, AKt silencing
by Akt siRNA and Pi3K inhibitor prevented Snail activity and
migration. Furthermore, the authors injected ghrelin knock-out
786-0 cell lines into nude-mice and found that metastatic lung
nodule numbers were significantly lower in ghrelin knocked-
out mice compared to the control group. In accordance
with in-vitro and in-vivo findings, higher local expression of
ghrelin was a significant and independent poor prognostic
factor in RCC patients. Higher ghrelin RNA expression was
also associated with risk of metastasis (85). Another study by
the same group examined other mechanisms underlying the
promoting effects of ghrelin on in-vitro local invasion and in-
vivo metastasis of RCC (126). Authors revealed the contribution
of ghrelin-GHSR1a-Aurora A-MMP10 signaling pathway to local
invasion and metastasis of RCC. Furthermore, by looking at
the cancer genome atlas (TCGA) database, the authors found
that tumor expression of ghrelin, Aurora A, and MMP-10 were
predictors of poor prognosis in RCC patients (Tables 1, 2;
Supplementary Table 6).
These two studies are good examples of the dominance of
ghrelin local effects on cancer cells revealed in in-vitro, in
summary clinical role of ghrelin in a type of cancer. It should be
considered that local expression of ghrelin in RCC tissue might
not necessarily reflect systemic levels of ghrelin in these patients
and the prognostic role of systemic ghrelin is yet to be inferred.
Nevertheless, it could be expected that the positive general roles
of systemic ghrelin (orexigenic and anti-inflammatory) have not
been able to overwhelm the notorious local effects in this cancer.
Brain Tumors
Overall, ghrelin exerts pro-oncogenic local effects on brain
tumors. Ghrelin and its receptor are expressed in different
types of astrocytoma cell-lines. Dixit et al. evaluated ghrelin
and GHSR1a expression in CCF-STTG1, U-87, U-118, and
SW1088 cell lines. GHSR expression was higher in these cell
lines compared to normal astrocytes. Ghrelin- GHSR binding
led to more cell motility. Ghrelin upregulated GHSR expression
and subsequently the motility via this receptor. This effect was
preventable by GHSR antagonist (86). In glioma, ghrelin induced
migration in both C6 rat cell-line and U251 human cell-line at
the concentration of 30 nM. Ghrelin increased cell migration via
GHSR, CaMK II, AMPK, and NF-kB pathways. NF-kβ binding
to DNA and subsequent kβ transcriptional activity was increased
(87) (Tables 1, 2; Supplementary Table 6).
The central nervous system expresses ghrelin under normal
condition. In a clinical study, ghrelin and GHSR1a expressions
were assessed by IHC in patients with glioblastoma, anaplastic
astrocytoma, and diffuse astrocytoma. Ghrelin expression was
observed in all glioblastoma, 12/13 anaplastic astrocytoma, and
2/11 diffuse astrocytoma patients. A similar pattern was observed
for GHSR1a expression. Based on age and ghrelin/GHSR
expression status, patients were classified into lower-score,
moderate, and high-score categories. Multivariable analysis of
overall survival indicated that survival rate was significantly
higher in the lower-score group compared to the high-
score group. No significant correlations were found between
ghrelin and GHS-R1a expression (88). Likewise, tumor GHSR
expression was associated with higher tumor size in patients with
neurofibromatosis 1 (89). Like RCC, this is another example of
dominance of in-vitro local findings in the summary clinical role
of ghrelin in a type of human cancer. Similar considerations for
prognostic roles of local vs. systemic ghrelin should be applied
here, too.
Gynecological Cancers
Ghrelin induced apoptosis in HO-8910 ovarian cancer cell-
line via GHSR-mediated ERK1/2 phosphorylation at the
concentration of 182 nM (90). Tissue expression levels of ghrelin
were different among three groups of patients with benign,
borderline, and malignant serous ovarian tumors (91). These
findings may imply ghrelin contribution to carcinogenesis of this
type of cancer.
Another study examined ghrelin role in endometrial cancer in
three sections of in-vitro, in-vivo, and human tissue microarray
assay. They observed 1,000 nM dose of exogenous acylated
ghrelin enhanced cell proliferation in intact cell-lines. This
effect was not seen for des-acylated ghrelin. In addition,
GSHR1a knock-out cell lines showed reduced proliferation in
the presence or absence of exogenous ghrelin, regardless of
dose or type (Tables 1, 2; Supplementary Table 6). Accordingly,
the increase in tumor size was slighter in NOD/SCID mice
injected with GHSR-1a knock-out Ishikawa cell line compared to
mice receiving intact Ishikawa cell line. Microarray tissue assay
detected ghrelin and GHSR1a expressions in both benign and
cancerous tissue specimen (92). These findings may emphasize
the pro-oncogenic role of ghrelin in endometrial cancer, mainly
mediated by acylated ghrelin-GHSR1a axis.
Another clinical study demonstrated lower tissue expressions
of ghrelin in cancerous tissue compared to hyperplastic
endometrial tissue. This study did not investigate ghrelin
expression in normal tissue. Decreased ghrelin level might be a
differential diagnosis marker in distinguishing carcinoma from
hyperplasia (93).
Oral Squamous Cell Carcinoma
Exogenous acylated ghrelin at doses of 100 nM−1µM enhanced
cell proliferation of BHY and HN oral SCC cell-lines. This
effect was mediated by GSK-3B/beta-catenin pathway and up-
regulation of cyclin-D1 and c-myc (94). Although this effect
was more pronounced in HN cell-line, this cell-line had a lower
expression of GHSR1a and a higher expression of GHSR1b
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FIGURE 3 | Model proposed to describe summary clinical role of ghrelin in case of each cancer. The figure summarizes the potential local and systemic effects of
ghrelin attributable to cancer biology (items listed in two purple boxes) as wells as the candidate factors that regulate these effects (the items inside surrounding
circles). Furthermore, the potential mechanisms proposed so far for local effects of ghrelin are listed in the purple box below the list of local effects. The superscript
numbers above each local effect correspond to the potential underlying mechanism(s) from the mechanisms list. The summary clinical role of ghrelin is built-up by
relative contributions of local and systemic effects. Based on the direction and relative dominance of local and systemic effects, the summary effect on different
aspects of cancer (the items in red box) could be promoting or protective.
compared to BHY cell-line (Tables 1, 2; Supplementary Table 6).
This may imply contribution of receptors other than GHSR1a
to ghrelin local effects on oral SCC cell-lines. Another clinical
study reported lower tissue expression of acylated and des-
acylated ghrelin in oral SCC specimen compared to adjacent
non-malignant tissue. This finding could have diagnostic
implications (95).
DISCUSSION
To address the inconsistencies across studies reporting local
effects of ghrelin on different cancer cell-lines, we scrutinized
potential factors that regulate/modify cell response to local
ghrelin. Some of these factors were inherent to the type of cell-
line (e.g., type of ghrelin receptor) and some of them were related
to the ghrelin (e.g., type and dose of ghrelin peptide) studied.
For controversies between findings of in-vitro and in-vivo/clinical
studies on the same type of cancer, we delineated local and
systemic effects of ghrelin on each cancer and discussed the final
summary effects observed based on an interaction between local
and systemic effects (Figure 3; Table 2). Some effects of ghrelin
occur in both local and systemic scales (e.g., anti-inflammatory).
Each local and systemic effect of ghrelin could be in favor
or against development and progress of corresponding type
of cancer.
Factors Regulating Local Effects
Type of Ghrelin Receptor
Type of ghrelin receptor on cell membrane can determine local
effects of ghrelin on each tissue/cell-line. Emerging evidence
implies that GHSR1a might not be responsible for all ghrelin-
mediated effects (25). Des-acylated ghrelin has low binding
affinity for this receptor, while recently found to be biologically
active (16, 133, 134). Many of the effects attributable to acylated
or des-acylated ghrelin could be mediated by other receptors,
which are yet to be characterized (25).
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Expression of ghrelin receptors is varied among different
types of human cancers. Breast and colon cancer cell lines
express both GHSR1a and GHSR1b (11, 29, 35). However,
ghrelin receptors were not notably expressed in lung cancer
cell-lines, specifically in non-endocrine subtype (75, 116).
Differential expression of ghrelin receptors was even observed
among different cell-lines of the same type of cancer. Unlike
other breast cancer cell lines, MDA-MB-231 cell-line expressed
only very small amounts of GHSR1a (12). Such a variance
also could be expected in expression of unidentified ghrelin
receptors. Differential expression of ghrelin receptors would
result in varied local effects of ghrelin on tumor cells. Extrinsic
ghrelin administration increased proliferation of MDA-MB-
231 and MDA-MB-435, but not MCF-7 breast cancer cell
lines (11).
Furthermore, despite negligible differences in expression of
GHSR1a between normal and cancerous breast tissues, GHSR1b
was notably upregulated in cancerous tissue compared to normal
tissue (11, 12). Similarly, although normal and malignant human
colon cell lines expressed both GHSR1a and GHSR1b, only
GHSR1b was upregulated in malignant cells compared to normal
tissue (35). Unlike GHSR1a, GHSR1b was positively associated
with tumor stage. These observations may imply a more
important role of GHSR1b in cancer biology.
Different levels of receptor expression was also seen among
tissue samples taken from different stages of a particular cancer
(35). With increased stages of disease in colorectal cancer
patients, expression of GHSR1a declined whereas expression of
GHSR1b increased. This could result in different responses to
ghrelin by tumors of different stages. A recent nested case control
reported a specific pattern of ghrelin effects on development of
colorectal cancer (30). While cancer risk was inversely correlated
with serum ghrelin measured within 10 years before diagnosis
of cancer, cancer risk increased with higher levels of serum
ghrelin measured more than 20 years before diagnosis. In
other words, exposure to higher systemic ghrelin resulted in
different effects on cancer development depending on the type
of pre-cancerous lesion in the time-line of cancer development,
exposed. This could be, in part, due to different expression
patterns of ghrelin receptors in lesions with different degrees of
malignant transformation.
Type of Ghrelin Peptide and Its Splice Variants
Each type of ghrelin peptide and its derivatives could have
different local effects on cell lines. Acylated and des-acylated
ghrelins have similar local effects on human breast (29), lung
(75), and gastric cancer (47) cell lines. Seemingly, two natural
ghrelins have similar local behavior in most cancer cell-lines
investigated. These observationsmay also imply that two ghrelins
use common, still unidentified, receptors in addition to GHSRs,
because des-acylated ghrelin has much less affinity to known
GHSRs (135). Exceptionally, although acylated ghrelin enhanced
cell proliferation in endometrial cancer cell lines, des-acylated
ghrelin did not exert proliferative effects (92). Authors observed a
significant role of GHSR1a in the cellular growth of endometrial
cancer cell-lines, which might explain contradicting results
observed for acylated and des-acylated ghrelin.
Native ghrelin showed different local effects on breast
cancer cell lines compared to its splice variants, exon 3-
deleted preproghrelin and intron-1 retained (Int-1). While
the expression of full-length preproghrelin was similar
between benign and malignant cell-lines (11), exon 3-
deleted preproghrelin mRNA was significantly upregulated
in malignant breast tissue and was associated with tumor
grade (11). Upregulation of exon 3-deleted preproghrelin
was also observed in some malignant cell lines, specifically
those negative for ER and PR (11). Likewise, transcription of
In1-ghrelin was upregulated 8-folds in high-grade tumor tissue
compared to normal breast tissue (12), and was associated
with poor survival (59). Furthermore, expression of In1-ghrelin
was highly associated with rate of cellular proliferation and
expression of GHSR1b, but not with expression of GHSR1a.
Unlike association of ghrelin with ER expression, no association
between In1-ghrelin and ER was observed (12). Based on these
findings, authors postulated that exon 3-deleted preproghrelin
and In1-ghrelin may have a more important role in breast cancer
progression, compared to native ghrelin.
Similarly, acylated, exon 3-deleted, and In1-ghrelins had
different local effects on prostate cancer cell line (36). Overall,
In1-ghrelin showed more oncogenic effects compared to
native ghrelin.
Factors Related to Experiment Setting
Ghrelin has dose-dependent local effects on some cancer cell-
lines. The prototype is gastric adenocarcinoma cell-line (47, 78)
where a biphasic pattern for stimulatory effects of acylated
and des-acylated ghrelins has been observed. While treatment
with 1 and 10 nm/l ghrelin increased the proliferation rate,
100 nm/l ghrelin caused an inhibitory effect on proliferation.
The stimulatory effect of 1 nm/l ghrelin was weaker than
the 10 nm/l dose. Interestingly, plasma ghrelin showed a
biphasic prognostic role in patients with gastric adenocarcinoma
when it was measured prior to gastrectomy while the tumor
tissue is still exposed to ghrelin (134). Patients with the
lowest and highest quartiles of pre-operative blood ghrelin
had higher rates of survival compared to those with ghrelin
levels in the range of 2nd−3rd quartiles. The prognostic
pattern of post-operative ghrelin was different. Extrinsic ghrelin
had biphasic local effects on breast and pancreas cancer
cells, too. In a more general trend suggested by a review,
lower doses of ghrelin enhanced proliferation rate and doses
>1µm exerted inhibitory effects on human cancer cell-lines
(52). Similarly, baseline serum ghrelin demonstrated a dose-
dependent protective role against 10-year risk of esophagus SCC
(72). Ghrelin also had dose-dependent effects on angiogenesis.
Treatment with lower concentrations increased angiogenesis,
while concentrations over 100 nM exerted inhibitory effects
(39). Whether in general or just in case of some specific
types of cancer, dose/concentration of ghrelin seems to be
an important regulatory factor in local and systemic effects
of ghrelin.
Another potential regulatory factor related to experiment
setting is represented by the constituents of culture media. Using
materials such as 4-(2-aminoethyl) benzene-sulphonyl fluoride
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hydrochloride has been suggested to influence the local effects of
ghrelin by interfering in de-acetylation process (136). However,
this theory is contradicted by the almost comparable effects of
ghrelin with des-acylated ghrelin observed in the studies that
investigated them both (29, 47, 75).
Given the de-acylation ability of serum esterase and short half-
life of acylated ghrelin in blood stream, it could be postulated that
different storage, processing, and analyzing methods of serum
samples may result in heterogenous estimates of circulating
acylated and des-acylated ghrelins in in-vivo and clinical studies.
Implementing a standard and consistent protocol for processing
[e.g., adding HCL to plasma samples (132)], storage, and
measurement of samples can address this issue.
Extent of Exposure of Tumor Cells to Local and
Systemic Ghrelin in Body
Ghrelin is mainly produced by the stomach and some other
organs such as kidney, intestine, and endocrine tissues (2,
5). It could be hypothesized that tumors originating within
or in adjacent to these organs may have higher paracrine
exposures to ghrelin. Therefore, in-situ local effects of ghrelin
on tumors originated from these organs may contribute more
prominently to the summary effects of ghrelin on carcinogenesis
or behavior of the tumor. In support, the prognostic pattern
of pre-operative blood ghrelin in patients with gastric cancer
(134) was in line with the pattern of ghrelin local effects
observed in in-vitro studies (47). However, the prognostic
role of ghrelin measured after gastrectomy, when tumor cells
are no longer exposed to paracrine ghrelin produced by the
stomach, was distinctly different and more justifiable by ghrelin
systemic effects (134). Similar dominancy of local effects in
summary role of ghrelin was observed in case of renal cell
carcinoma (85) and colorectal carcinoma (30). Another potential
example could be the gastrointestinal stromal tumor (GIST)
in stomach (137). However, current data is scarce about
contribution of ghrelin to development or prognosis of this
cancer. On the other hand, physiologic barriers may limit access




One of the well-studied systemic effects of ghrelin in body is
stimulation of appetite (73). Ghrelin has long been considered
as a potential treatment for cancer-associated cachexia (138–
140). Improving effects of ghrelin on food intake and body
composition have been reported in patients with different types
of cancer (120, 140, 141). Regarding documented poor prognostic
role of cachexia in cancer patients (142), orexigenic effects of
body ghrelin could be considered an invariable positive piece in
the puzzle of ghrelin contribution to cancer prognosis, regardless
of cancer type.
Anti-inflammatory
Chronic inflammation pre-disposes to tumorigenesis in
different types of cancers. Local inflammation is linked
to tumor microenvironments and cancer progression
(40, 41). Ghrelin has both general and site-specific anti-
inflammatory effects. In general, it mitigates production of
pro-inflammatory cytokines (TNFα, IL-1β, IL-6, and IL-8)
and nuclear factor κB. Both ghrelin and des-acylated ghrelin
suppress macrophage-originated inflammatory cytokines and
expression of COX-2 (143). Furthermore, ghrelin can activate
gastric vagus nerve that conveys immune information of the
GI tract to the hypothalamus (144, 145). Vagus stimulation
reduces macrophage-originated chemokines and attenuates
inflammatory response in GI tract mucosa (133, 146).
Ghrelin could also attenuate inflammation in epithelial cells of
colon (6).
The anti-inflammatory effects of ghrelin can protect against
carcinogenesis, specifically in case of inflammation-derived
cancers. Ghrelin inhibited carcinogenesis in mouse model of
inflammation-associated colorectal cancer (42). At the same
study, ghrelin could not prevent carcinogenesis in APC-mutated
mice, emphasizing the importance of anti-inflammatory effects of
ghrelin in preventing carcinogenesis in inflammation-mediated
model. Similarly, ghrelin had inhibitory effects on esophageal
Barret’s carcinogenesis by opposing inflammation (69).
Furthermore, inflammation contributes to cachexia and
cancer metastasis, both of which are notorious prognostic factors
in cancer (134). Therefore, the anti-inflammatory effects of
ghrelin could be considered an invariable positive contributor to
cancer survival, regardless of cancer type. Orexigenic and anti-
inflammatory effects of ghrelin could explain better prognosis of
gastric cancer patients with post-operative blood ghrelin in range
of higher quartiles (134).
Regulation of Endocrine Function
Ghrelin regulates some endocrine function with potential
contributions to cancer biology. Inhibitory effects of both native
ghrelins on expression and activity of aromatase enzyme in
adipose stromal cells is the prototype example (136, 144).
Aromatase-mediated production of estrogen in peripheral
adipose tissue is the major driver of hormone-dependent
breast cancer and its aggressiveness in post-menopausal
women (144). This underlines the efficacy of estrogen
receptor antagonist or aromatase inhibitors in hormone-
dependent breast cancer patients. Based on a similar rationale,
ghrelin could be both protective against carcinogenesis and
a positive prognostic factor in estrogen-dependent breast
cancer. It also could be considered an adjuvant therapy
like other novel therapies suggested (147, 148) to reduce
toxicity of conventional therapies (149). In support, three
cohorts reported positive prognostic significance of ghrelin
immunostainings in breast cancer tissue (96, 97, 103). These
cohorts consisted of men or women patients with hormone-
dependent breast cancer and mean age of women cases was in
post-menopausal range.
Another endocrine effect of ghrelin potentially attributable to
cancer biology is its stimulation of growth hormone secretion by
binding to GHSR1a. GH regulates serum concentrations of IGF1
that has pro-neoplastic effects (150). However, existing evidence
does not strongly support contribution of ghrelin-GH-IGF1 axis
to cancer development or progression.
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Recommendations for Future in-vitro and
Clinical Studies
We underscored some potential factors regulating local effects of
ghrelin. There is no comprehensive single study on one type of
cancer to have investigated all these factors together. This is a
limitation for interpreting potential roles of these factors in case
of a single cancer. The regulating factors highlighted here should
be considered in designing future in-vitro studies.
Separate and pooled interpretations of local and systemic
effects of ghrelin on each type of cancer and consideration of
the role of regulating factors could help evaluate the rational
for conducting clinical trials investigating exogenous ghrelin on
patients with corresponding cancer.
There is vast heterogeneity in the design of experiments,
assessment techniques, and dose and type of materials used.
This limits the possibility to compare the results of studies on
different cell-lines. The majority of current clinical trials reported
short-term effects of ghrelin on appetite and body composition
of cancer patients. Longer-term effects of exogenous ghrelin on
cancer progress and prognosis would shed further lights on
clinical applicability of exogenous ghrelin.
CONCLUSIONS
Current literature shows controversies in attribution of ghrelin
to cancer. To address controversial results between local effects
of ghrelin on different tumor cells, we attempted to scrutinize
factors that could regulate ghrelin local effects. Type of ghrelin
receptor, type of ghrelin peptide and its splice variants, dose of
ghrelin and other experimental settings, and local access of tumor
cells to ghrelin in body were main factors supposed to regulate
local effects of ghrelin. To address apparent discrepancies
between in-vitro and clinical studies of ghrelin attribution to
one type of cancer, we delineated local and systemic effects of
ghrelin and interpreted the final clinical role as a summary of
local and systemic effects. Future in-vitro and clinical studies are
recommended to consider these approaches in their study design.
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